This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
staphylococcus aureus | 192 |
respiratory tract | 177 |
clinical isolates | 164 |
lg ml | 151 |
respiratory viruses | 126 |
infectious diseases | 121 |
risk factors | 109 |
resistant strains | 104 |
antibiotic resistance | 99 |
intensive care | 95 |
acute respiratory | 92 |
tract infections | 91 |
antimicrobial agents | 87 |
time pcr | 83 |
escherichia coli | 83 |
strains isolated | 80 |
mcg ml | 79 |
acquired pneumonia | 79 |
susceptibility testing | 79 |
vitro activity | 79 |
mg kg | 77 |
public health | 76 |
present study | 75 |
clin microbiol | 75 |
influenza virus | 73 |
microbiol infect | 72 |
cord uid | 72 |
doc id | 72 |
infect doi | 72 |
streptococcus pneumoniae | 71 |
antimicrobial resistance | 70 |
hospitalized patients | 70 |
blood cultures | 69 |
infection control | 68 |
resistance genes | 67 |
tract infection | 67 |
respiratory syncytial | 67 |
mean age | 64 |
syncytial virus | 64 |
novel coronavirus | 64 |
coronavirus disease | 64 |
fever rs | 63 |
clostridium difficile | 62 |
performed using | 62 |
mic values | 61 |
broth microdilution | 61 |
rs group | 61 |
pseudomonas aeruginosa | 61 |
antibiotic treatment | 61 |
antibiotic use | 59 |
disk diffusion | 58 |
cfu ml | 58 |
blood culture | 58 |
lower respiratory | 57 |
urinary tract | 56 |
clinical microbiology | 56 |
antibiotic therapy | 55 |
study period | 55 |
gel electrophoresis | 54 |
control group | 54 |
pcr assay | 54 |
statistically significant | 53 |
clinical samples | 53 |
broad spectrum | 52 |
agar dilution | 52 |
resistant staphylococcus | 51 |
clinical trials | 51 |
university hospital | 51 |
multiplex pcr | 51 |
care unit | 51 |
respiratory virus | 51 |
resistant isolates | 50 |
least one | 49 |
cohort study | 48 |
infectious disease | 47 |
antimicrobial therapy | 47 |
antimicrobial susceptibility | 47 |
chain reaction | 46 |
respiratory infections | 46 |
bacterial pathogens | 45 |
viral load | 45 |
field gel | 44 |
infections caused | 44 |
nucleic acid | 44 |
antibiotic susceptibility | 44 |
mrsa isolates | 43 |
respiratory syndrome | 43 |
primary care | 43 |
chlamydia pneumoniae | 43 |
polymerase chain | 42 |
log cfu | 42 |
reduced susceptibility | 42 |
macrolide resistance | 42 |
year period | 41 |
virus infection | 41 |
significant differences | 40 |
severe acute | 40 |
adverse events | 40 |
negative staphylococci | 40 |
years old | 40 |
soft tissue | 40 |
risk factor | 40 |
influenza viruses | 39 |
critically ill | 39 |
per patient | 38 |
adult patients | 38 |
species level | 38 |
pregnant women | 38 |
determined using | 38 |
pcr assays | 37 |
logistic regression | 37 |
age group | 37 |
helicobacter pylori | 37 |
mrsa strains | 37 |
diffusion method | 37 |
patients admitted | 36 |
among patients | 36 |
blood samples | 36 |
respiratory pathogens | 36 |
amino acid | 36 |
negative bacteria | 36 |
drug resistance | 35 |
respiratory symptoms | 35 |
clavulanic acid | 35 |
significant difference | 35 |
positive samples | 35 |
negative predictive | 35 |
pk pd | 35 |
aureus isolates | 34 |
agar plates | 34 |
bactericidal activity | 34 |
health care | 34 |
auc mic | 34 |
viral infections | 34 |
candida spp | 34 |
hong kong | 34 |
sequence analysis | 34 |
ill patients | 33 |
mic mg | 33 |
hospital stay | 33 |
bacterial strains | 33 |
resistance rates | 33 |
significantly higher | 33 |
predictive value | 33 |
klebsiella pneumoniae | 33 |
patients received | 32 |
nosocomial infections | 32 |
bacterial infections | 32 |
one patient | 32 |
piperacillin tazobactam | 32 |
nccls guidelines | 32 |
cerebrospinal fluid | 32 |
united states | 32 |
per cent | 32 |
clinical specimens | 32 |
positive blood | 31 |
mortality rate | 31 |
spectrum beta | 31 |
prospective study | 31 |
respiratory viral | 31 |
dilution method | 31 |
clinical characteristics | 31 |
positive strains | 31 |
infected patients | 31 |
european countries | 30 |
two strains | 30 |
upper respiratory | 30 |
patients treated | 30 |
species identification | 30 |
generation cephalosporins | 30 |
last years | 30 |
resistance among | 30 |
rrna gene | 29 |
patients without | 29 |
drug resistant | 29 |
median age | 29 |
hospitalised patients | 29 |
patients hospitalized | 29 |
two groups | 29 |
respiratory specimens | 29 |
inhibitory concentration | 28 |
healthy volunteers | 28 |
virulence genes | 28 |
haemophilus influenzae | 28 |
systematic review | 28 |
bacterial meningitis | 28 |
human metapneumovirus | 28 |
positive bacteria | 28 |
clinical features | 28 |
frequently detected | 28 |
aureus strains | 28 |
one isolate | 28 |
gram negative | 28 |
community acquired | 28 |
molecular testing | 28 |
enterococcus faecalis | 28 |
quality control | 28 |
antibacterial activity | 27 |
data suggest | 27 |
virulence factors | 27 |
mic mic | 27 |
antimicrobial activity | 27 |
intravenous antibiotics | 27 |
three different | 27 |
molecular typing | 26 |
complicated skin | 26 |
mg ml | 26 |
quinupristin dalfopristin | 26 |
study group | 26 |
high prevalence | 26 |
two patients | 26 |
diagnostic tests | 26 |
microdilution method | 26 |
hand hygiene | 26 |
acinetobacter baumannii | 26 |
acinetobacter spp | 26 |
patients receiving | 26 |
bone marrow | 26 |
tissue infections | 26 |
comprehensive molecular | 26 |
stool samples | 26 |
reactive protein | 26 |
high level | 26 |
age groups | 25 |
two different | 25 |
tetracycline resistance | 25 |
antibiotic consumption | 25 |
anaerobic bacteria | 25 |
resistance determinants | 25 |
randomized controlled | 25 |
controlled trial | 25 |
icu patients | 25 |
commonly used | 25 |
commercially available | 24 |
hospital admission | 24 |
teaching hospital | 24 |
care units | 24 |
closely related | 24 |
clinical trial | 24 |
recent years | 24 |
clinical data | 24 |
respiratory infection | 24 |
molecular methods | 24 |
positive isolates | 24 |
control measures | 24 |
microbiology laboratories | 24 |
supplementary material | 24 |
analysis showed | 23 |
invasive aspergillosis | 23 |
structure infections | 23 |
resistance phenotype | 23 |
pneumoniae isolates | 23 |
serum samples | 23 |
binary toxin | 23 |
clinically relevant | 22 |
infections due | 22 |
clinical practice | 22 |
well tolerated | 22 |
intervention group | 22 |
negative bacilli | 22 |
mg bid | 22 |
widely used | 22 |
patients infected | 22 |
nasopharyngeal swab | 22 |
significantly associated | 22 |
klebsiella spp | 22 |
enzyme immunoassay | 22 |
high risk | 22 |
methicillin resistant | 22 |
factors associated | 22 |
antigen detection | 22 |
syndrome coronavirus | 22 |
imi cis | 22 |
respiratory failure | 22 |
coli isolates | 22 |
minimum inhibitory | 21 |
atypical pathogens | 21 |
diabetes mellitus | 21 |
respiratory illness | 21 |
older age | 21 |
informed consent | 21 |
statistical analysis | 21 |
elderly patients | 21 |
rapid detection | 21 |
total number | 21 |
mg dl | 21 |
positive results | 21 |
analysed using | 21 |
extended spectrum | 21 |
automated surveillance | 21 |
healthcare workers | 21 |
rna extraction | 21 |
igm antibodies | 21 |
fangcang shelter | 21 |
genes encoding | 21 |
previous studies | 21 |
positive specimens | 21 |
faecal samples | 21 |
pcr method | 21 |
immunocompromised patients | 21 |
susceptible strains | 21 |
one hundred | 21 |
young children | 20 |
infective endocarditis | 20 |
wild type | 20 |
positive cocci | 20 |
group i | 20 |
pcr amplification | 20 |
specific primers | 20 |
decreased susceptibility | 20 |
two isolates | 20 |
biofilm formation | 20 |
bacterial infection | 20 |
clinical studies | 20 |
three patients | 20 |
patients hospitalised | 20 |
important role | 20 |
confidence interval | 20 |
resistance patterns | 20 |
clinical strains | 20 |
resistance mechanisms | 20 |
results suggest | 20 |
enterococcus faecium | 20 |
viral pathogens | 20 |
study showed | 20 |
emergency department | 20 |
heart failure | 20 |
enterococcus spp | 20 |
previously described | 20 |
treated patients | 20 |
central laboratory | 20 |
invasive fungal | 20 |
general population | 20 |
regression model | 19 |
clinical significance | 19 |
lrti patients | 19 |
gold standard | 19 |
associated pneumonia | 19 |
cell wall | 19 |
difficile strains | 19 |
mg iv | 19 |
sample size | 19 |
avian influenza | 19 |
patient days | 19 |
pylori infection | 19 |
day mortality | 19 |
nervous system | 19 |
pcr products | 19 |
transplant recipients | 19 |
internal control | 19 |
genomic dna | 19 |
virus infections | 19 |
esbl producing | 19 |
medical staff | 19 |
mic ratio | 19 |
disease severity | 19 |
shiga toxin | 19 |
performed according | 19 |
skin structure | 19 |
esbl production | 19 |
negative results | 19 |
strains showed | 19 |
interpreted according | 19 |
real time | 19 |
clinical manifestations | 18 |
staphylococcus spp | 18 |
tested using | 18 |
pg ml | 18 |
dna sequencing | 18 |
clinical outcomes | 18 |
gram positive | 18 |
observational study | 18 |
diagnostic methods | 18 |
one strain | 18 |
world health | 18 |
clinical management | 18 |
hinton agar | 18 |
high rate | 18 |
may also | 18 |
associated diarrhoea | 18 |
tertiary care | 18 |
reference standard | 18 |
multivariate analysis | 18 |
gastric cancer | 18 |
filmarray rp | 18 |
protein binding | 18 |
reverse transcription | 18 |
mean duration | 18 |
empiric therapy | 18 |
time rt | 18 |
resistance phenotypes | 18 |
erythromycin resistance | 18 |
surveillance system | 18 |
method according | 18 |
among children | 18 |
antibiotics tested | 18 |
multidrug resistant | 18 |
severe infections | 18 |
university hospitals | 18 |
coli strains | 18 |
case report | 18 |
observational studies | 18 |
north america | 18 |
negative rods | 17 |
see table | 17 |
ml min | 17 |
therapeutic option | 17 |
positive result | 17 |
viral pneumonia | 17 |
kill curves | 17 |
ddd tid | 17 |
nalidixic acid | 17 |
clinical success | 17 |
group ii | 17 |
inhibitory concentrations | 17 |
common pathogens | 17 |
amoxicillin clavulanate | 17 |
significantly increased | 17 |
glycopeptide resistance | 17 |
pancreatic tissue | 17 |
pulmonary disease | 17 |
cell culture | 17 |
vitro susceptibility | 17 |
reference strains | 17 |
antifungal therapy | 17 |
clinically significant | 17 |
bloodstream infections | 17 |
phylogenetic analysis | 17 |
viral respiratory | 17 |
results obtained | 17 |
viral rna | 17 |
see supplementary | 17 |
interquartile range | 17 |
epithelial cells | 17 |
diagnostic accuracy | 17 |
medical centres | 17 |
causative agent | 17 |
severe covid | 17 |
per year | 16 |
isolates recovered | 16 |
cap patients | 16 |
sequence typing | 16 |
subjects received | 16 |
microdilution panels | 16 |
bacterial growth | 16 |
mechanical ventilation | 16 |
clinical cure | 16 |
large number | 16 |
one case | 16 |
wide range | 16 |
pneumoniae strains | 16 |
central nervous | 16 |
cns infections | 16 |
faecium isolates | 16 |
isolates collected | 16 |
acquired infections | 16 |
viral infection | 16 |
spectrum activity | 16 |
major cause | 16 |
apache ii | 16 |
susceptibility tests | 16 |
clinical response | 16 |
retrospective study | 16 |
predictive values | 16 |
machine learning | 16 |
antimicrobial prophylaxis | 16 |
immune response | 16 |
significantly different | 16 |
tested positive | 16 |
controlled trials | 16 |
rapid test | 16 |
septic shock | 16 |
laboratory using | 15 |
univariate analysis | 15 |
moderate covid | 15 |
six patients | 15 |
clinical course | 15 |
icu admission | 15 |
prospective cohort | 15 |
staphylococcus epidermidis | 15 |
inclusion criteria | 15 |
odds ratios | 15 |
resistant gram | 15 |
united kingdom | 15 |
including methicillin | 15 |
square test | 15 |
respiratory panel | 15 |
streptococcus pyogenes | 15 |
three isolates | 15 |
strains belonging | 15 |
seasonal influenza | 15 |
bacteroides fragilis | 15 |
fungal infections | 15 |
common among | 15 |
nasopharyngeal swabs | 15 |
isolates showed | 15 |
disc diffusion | 15 |
manual surveillance | 15 |
case reports | 15 |
blood agar | 15 |
test results | 15 |
candida species | 15 |
retrospective cohort | 15 |
regression analysis | 15 |
shelter hospitals | 15 |
clinical isolate | 15 |
mrsa infections | 15 |
surveillance program | 15 |
low level | 15 |
resistant enterococci | 15 |
clinical laboratories | 15 |
resistance rate | 15 |
nosocomial infection | 15 |
single dose | 15 |
hinton broth | 15 |
clinical diagnosis | 14 |
bacterial co | 14 |
mortality rates | 14 |
coagulase negative | 14 |
hospital mortality | 14 |
case series | 14 |
within days | 14 |
underlying disease | 14 |
identified using | 14 |
care hospitals | 14 |
previous study | 14 |
lowest mic | 14 |
molecular epidemiology | 14 |
results show | 14 |
common cause | 14 |
confirmed cases | 14 |
obstructive pulmonary | 14 |
health organization | 14 |
strains tested | 14 |
ab biodisk | 14 |
antifungal susceptibility | 14 |
compared using | 14 |
expression levels | 14 |
new class | 14 |
included patients | 14 |
drinking water | 14 |
difficile infection | 14 |
abdominal pain | 14 |
within hours | 14 |
phase i | 14 |
herpes simplex | 14 |
antibiotic prescribing | 14 |
four different | 14 |
akacid plus | 14 |
younger age | 14 |
significant increase | 14 |
copies ml | 14 |
high mortality | 14 |
type strains | 14 |
results indicate | 14 |
severe sepsis | 14 |
patient population | 14 |
treatment groups | 14 |
results showed | 14 |
class integrons | 14 |
valve endocarditis | 14 |
relatively low | 14 |
vitek system | 14 |
healthy subjects | 14 |
differential diagnosis | 14 |
laboratory findings | 14 |
respiratory distress | 14 |
isolated strains | 14 |
bacterial isolates | 14 |
empiric treatment | 14 |
expanded broad | 14 |
pcr using | 14 |
resistance gene | 14 |
clinical presentation | 14 |
test program | 14 |
cure rates | 14 |
may lead | 14 |
hospital acquired | 14 |
enterobacter spp | 14 |
cell count | 14 |
renal failure | 14 |
five isolates | 14 |
selective pressure | 14 |
urine samples | 14 |
underlying diseases | 14 |
acute care | 13 |
positive cultures | 13 |
study shows | 13 |
early diagnosis | 13 |
diabetic foot | 13 |
corticosteroid treatment | 13 |
plasma concentrations | 13 |
saudi arabia | 13 |
igg antibodies | 13 |
ft mic | 13 |
mean time | 13 |
pulmonary aspergillosis | 13 |
month period | 13 |
two cases | 13 |
resistance mechanism | 13 |
prosthetic valve | 13 |
clinical laboratory | 13 |
outer membrane | 13 |
negative strains | 13 |
amoxicillin clavulanic | 13 |
human rhinovirus | 13 |
respiratory samples | 13 |
resistance profile | 13 |
diagnostic test | 13 |
upper airway | 13 |
care workers | 13 |
using standard | 13 |
atrophic gastritis | 13 |
pandemic influenza | 13 |
tertiary hospital | 13 |
first case | 13 |
pcr testing | 13 |
middle ear | 13 |
infection among | 13 |
pfge patterns | 13 |
nursing homes | 13 |
culture positive | 13 |
common respiratory | 13 |
nine patients | 13 |
producing strains | 13 |
mic range | 13 |
high resistance | 13 |
statistical analyses | 13 |
treatment failure | 13 |
serum concentrations | 13 |
ct scan | 13 |
fusidic acid | 13 |
correctly identified | 13 |
agglutination test | 13 |
older adults | 13 |
bacterial species | 13 |
routine methods | 13 |
determine whether | 13 |
chronic obstructive | 13 |
eradication rates | 13 |
microdilution methods | 13 |
analysis revealed | 13 |
side effects | 13 |
corticosteroid therapy | 13 |
carbapenem resistance | 13 |
lactam antibiotics | 13 |
streptococcus agalactiae | 13 |
antibiotic prescription | 13 |
susceptibility patterns | 13 |
secondary infections | 13 |
retrospective analysis | 13 |
blood cell | 13 |
cq hcq | 13 |
specific antibodies | 13 |
medical records | 13 |
lactamase production | 13 |
fragilis group | 13 |
type i | 13 |
statistical significance | 13 |
typing methods | 13 |
paediatric patients | 13 |
using pcr | 13 |
incidence rate | 13 |
nosocomial pneumonia | 13 |
first time | 13 |
virus rna | 13 |
physical examination | 13 |
pooling strategy | 12 |
extraction method | 12 |
control study | 12 |
gene sequence | 12 |
isolates tested | 12 |
resistant streptococcus | 12 |
minimal inhibitory | 12 |
exact test | 12 |
adverse event | 12 |
different groups | 12 |
patient management | 12 |
pcr results | 12 |
mixed infections | 12 |
lactamase genes | 12 |
presented data | 12 |
swab samples | 12 |
attack rate | 12 |
recently described | 12 |
penicillin resistant | 12 |
gene encoding | 12 |
whole blood | 12 |
pcr reaction | 12 |
also found | 12 |
peptide deformylase | 12 |
serious infections | 12 |
type ii | 12 |
internal medicine | 12 |
animal models | 12 |
routine real | 12 |
mlsb phenotype | 12 |
cost per | 12 |
pathogens causing | 12 |
potent expanded | 12 |
overall incidence | 12 |
severe disease | 12 |
five patients | 12 |
hmpv patients | 12 |
tigecycline compared | 12 |
kg day | 12 |
aureus atcc | 12 |
white blood | 12 |
cohort studies | 12 |
may play | 12 |
pcr tests | 12 |
third generation | 12 |
currently available | 12 |
trimethoprim sulfamethoxazole | 12 |
different species | 12 |
resistant bacteria | 12 |
vancomycin aztreonam | 12 |
authors declare | 12 |
dyspeptic patients | 12 |
patients undergoing | 12 |
diabetic patients | 12 |
gene expression | 12 |
children aged | 12 |
cc isolates | 12 |
human coronavirus | 12 |
highly resistant | 12 |
studied period | 12 |
cranberry juice | 12 |
bacteroides spp | 12 |
difficile toxin | 12 |
virus survival | 12 |
isolates obtained | 12 |
detection rates | 12 |
antiviral treatment | 12 |
burn wounds | 12 |
tcid ml | 12 |
time points | 12 |
heart disease | 12 |
pulsed field | 12 |
food borne | 12 |
increasing number | 12 |
young adults | 12 |
latin america | 12 |
negative anaerobic | 12 |
success rates | 12 |
strains regardless | 12 |
listeria monocytogenes | 12 |
clinical efficacy | 12 |
tigecycline may | 12 |
analysis using | 12 |
type strain | 12 |
parainfluenza virus | 12 |
increased risk | 12 |
tap water | 12 |
baumannii strains | 12 |
quinolone resistance | 12 |
hp infection | 12 |
fragment length | 12 |
rt pcr | 12 |
strains resistant | 12 |
respiratory rate | 12 |
positive pathogens | 12 |
susceptibility rates | 12 |
mycoplasma pneumoniae | 12 |
renal function | 12 |
may provide | 12 |
vancomycin resistance | 12 |
vast majority | 12 |
confidence intervals | 12 |
excellent activity | 12 |
year old | 12 |
patients diagnosed | 12 |
nasal swabs | 12 |
intravenous antibiotic | 12 |
cefoperazone sulbactam | 12 |
immune system | 12 |
age years | 12 |
double disk | 12 |
positive test | 11 |
deformylase inhibitor | 11 |
albicans strains | 11 |
rapid diagnosis | 11 |
western blot | 11 |
conventional methods | 11 |
isolation units | 11 |
daily doses | 11 |
virus detected | 11 |
findings suggest | 11 |
aerobic gram | 11 |
last decade | 11 |
acquired mrsa | 11 |
agr group | 11 |
randomly selected | 11 |
aged years | 11 |
preliminary results | 11 |
european centre | 11 |
microbiology laboratory | 11 |
curve analysis | 11 |
may explain | 11 |
health problem | 11 |
disease prevention | 11 |
genital tract | 11 |
patients died | 11 |
participating site | 11 |
spectrum cephalosporins | 11 |
treatment duration | 11 |
local laboratory | 11 |
filmarray respiratory | 11 |
esbl producers | 11 |
multidrug resistance | 11 |
severe cap | 11 |
study included | 11 |
comparator agents | 11 |
simultaneous detection | 11 |
differ significantly | 11 |
bacterial resistance | 11 |
program determined | 11 |
different genotypes | 11 |
common bacterial | 11 |
higher risk | 11 |
horizontal transfer | 11 |
reference laboratory | 11 |
cmv infection | 11 |
bronchoalveolar lavage | 11 |
like illness | 11 |
isothermal amplification | 11 |
supplementary table | 11 |
nccls broth | 11 |
mg day | 11 |
recombinant proteins | 11 |
homeless patients | 11 |
broad range | 11 |
three cases | 11 |
prevotella spp | 11 |
viral loads | 11 |
primary outcome | 11 |
producing isolates | 11 |
acquired respiratory | 11 |
less susceptible | 11 |
national reference | 11 |
type esbls | 11 |
disease progression | 11 |
generation sequencing | 11 |
data collection | 11 |
penicillin resistance | 11 |
overall mortality | 11 |
transport medium | 11 |
old man | 11 |
median time | 11 |
inflammatory response | 11 |
candida albicans | 11 |
rapid diagnostic | 11 |
biopsy samples | 11 |
antimicrobial surveillance | 11 |
reliable therapeutic | 11 |
frequently isolated | 11 |
twice daily | 11 |
ms ms | 11 |
reference method | 11 |
infected mice | 11 |
patients included | 11 |
pilot study | 11 |
epi isl | 11 |
resistance pattern | 11 |
salmonella isolates | 11 |
written informed | 11 |
human cases | 11 |
patients suffering | 11 |
related infections | 11 |
level resistance | 11 |
antimicrobial treatment | 11 |
highly active | 11 |
nvp pdf | 11 |
general hospital | 11 |
four patients | 11 |
macrolide resistant | 10 |
symptom onset | 10 |
regression models | 10 |
days post | 10 |
clinical outcome | 10 |
molecular characterisation | 10 |
mass spectrometry | 10 |
duodenal ulcer | 10 |
renal impairment | 10 |
detected using | 10 |
studies showed | 10 |
commonly reported | 10 |
data obtained | 10 |
bacterial load | 10 |
evaluated using | 10 |
aspergillus spp | 10 |
studies using | 10 |
rapid identification | 10 |
oral dose | 10 |
group testing | 10 |
clinical symptoms | 10 |
multivariable logistic | 10 |
may help | 10 |
point prevalence | 10 |
hospital environment | 10 |
toxic shock | 10 |
common pathogen | 10 |
important factor | 10 |
renal insufficiency | 10 |
blister fluid | 10 |
endemic region | 10 |
class i | 10 |
valentine leukocidin | 10 |
spectrum antibiotics | 10 |
different regions | 10 |
positive pcr | 10 |
virulence factor | 10 |
small number | 10 |
electron microscopy | 10 |
clinically important | 10 |
mediated isothermal | 10 |
plates containing | 10 |
treponema pallidum | 10 |
causative organisms | 10 |
four isolates | 10 |
underlying conditions | 10 |
csf samples | 10 |
hospital infection | 10 |
review board | 10 |
using nccls | 10 |
mlsb resistance | 10 |
rrna genes | 10 |
frequently used | 10 |
capillary electrophoresis | 10 |
nasal carriage | 10 |
also tested | 10 |
positive culture | 10 |
middle east | 10 |
invasive candidiasis | 10 |
cystic fibrosis | 10 |
emm types | 10 |
otitis media | 10 |
tinea pedis | 10 |
respiratory disease | 10 |
full manual | 10 |
samples taken | 10 |
abdominal infections | 10 |
symptomatic patients | 10 |
negative pathogens | 10 |
low prevalence | 10 |
multilocus sequence | 10 |
blood stream | 10 |
spectrum antimicrobial | 10 |
nosocomial pathogens | 10 |
like gene | 10 |
cancer patients | 10 |
fragilis strains | 10 |
mg tid | 10 |
six strains | 10 |
rapid antigen | 10 |
length polymorphism | 10 |
quorum sensing | 10 |
computed tomography | 10 |
cns infection | 10 |
commonly prescribed | 10 |
study design | 10 |
cutaneous leishmaniasis | 10 |
bacterial pathogen | 10 |
influenza pandemic | 10 |
patients aged | 10 |
among gram | 10 |
pcr detection | 10 |
median duration | 10 |
north liberty | 10 |
several studies | 10 |
acute gastroenteritis | 10 |
specific pcr | 10 |
peripheral blood | 10 |
free drug | 10 |
high sensitivity | 10 |
susceptibility test | 10 |
pneumococcal pneumonia | 10 |
categorical variables | 10 |
previously published | 10 |
associated infections | 10 |
antimicrobial agent | 10 |
every hours | 10 |
phase iii | 10 |
monte carlo | 10 |
resistance levels | 10 |
bacterial counts | 10 |
oral microbiology | 10 |
relatively high | 10 |
genetic diversity | 10 |
myocardial infarction | 10 |
bacterial pneumonia | 10 |
increased mortality | 10 |
also detected | 10 |
room temperature | 10 |
hmpv infection | 10 |
parainfluenza viruses | 10 |
pylori isolates | 10 |
combination therapy | 10 |
patients showed | 10 |
serological tests | 10 |
different respiratory | 10 |
least two | 10 |
mrsa prevalence | 10 |
plasmid dna | 10 |
sccmec type | 10 |
hearing loss | 10 |
cough episodes | 10 |
clinical failure | 10 |
diagnostic yield | 10 |
epidemic strains | 10 |
severe respiratory | 10 |
metropolitan area | 10 |
incubation period | 10 |
type iv | 10 |
slime production | 10 |
czech republic | 10 |
within one | 10 |
potential role | 10 |
resistant gbs | 9 |
strains collected | 9 |
cpe gene | 9 |
culture isolates | 9 |
cardiovascular disease | 9 |
genome sequence | 9 |
leading cause | 9 |
high frequency | 9 |
observed among | 9 |
healthy adult | 9 |
new drugs | 9 |
human infections | 9 |
clindamycin resistance | 9 |
poor prognosis | 9 |
time kill | 9 |
enteral feeding | 9 |
streptococcal colonisation | 9 |
vital signs | 9 |
detection rate | 9 |
mycobacterium tuberculosis | 9 |
consecutive patients | 9 |
also resistant | 9 |
different countries | 9 |
institutional review | 9 |
serum specimens | 9 |
using broth | 9 |
sheep blood | 9 |
radiological procedure | 9 |
strains belonged | 9 |
test method | 9 |
acute bacterial | 9 |
strain types | 9 |
study population | 9 |
ciprofloxacin susceptibility | 9 |
ii score | 9 |
helicobacter species | 9 |
sensitivity analysis | 9 |
detection methods | 9 |
eradication therapy | 9 |
acute exacerbation | 9 |
samples obtained | 9 |
positive patients | 9 |
gram stain | 9 |
care hospital | 9 |
distress syndrome | 9 |
pneumococcal conjugate | 9 |
isolates belonged | 9 |
old female | 9 |
also used | 9 |
antifungal agents | 9 |
epidemic viruses | 9 |
dilution methods | 9 |
drug concentrations | 9 |
good correlation | 9 |
disease control | 9 |
randomly assigned | 9 |
iu ml | 9 |
influenza vaccination | 9 |
children years | 9 |
different types | 9 |
antiviral resistance | 9 |
pathogenic bacteria | 9 |
randomised controlled | 9 |
candida infections | 9 |
three strains | 9 |
burn wound | 9 |
restriction fragment | 9 |
agents tested | 9 |
significantly reduced | 9 |
many patients | 9 |
phylogenetic groups | 9 |
showed high | 9 |
infectious complications | 9 |
colony counts | 9 |
stool specimens | 9 |
dairy sheep | 9 |
data analysis | 9 |
fluoroquinolone resistance | 9 |
central venous | 9 |
previous months | 9 |
demographic data | 9 |
antibiotic policy | 9 |
patient care | 9 |
odds ratio | 9 |
done using | 9 |
immune responses | 9 |
better understanding | 9 |
significantly lower | 9 |
received grn | 9 |
dna extraction | 9 |
higher mortality | 9 |
well known | 9 |
genetic relatedness | 9 |
different viruses | 9 |
tissue infection | 9 |
drug classes | 9 |
standard methods | 9 |
samples collected | 9 |
blood pressure | 9 |
antimicrobial susceptibilities | 9 |
mg po | 9 |
prescribed antimicrobials | 9 |
difficile isolates | 9 |
ug ml | 9 |
normal flora | 9 |
melting curve | 9 |
dengue virus | 9 |
viral pcr | 9 |
pcr product | 9 |
study drug | 9 |
epidemiological studies | 9 |
male gender | 9 |
resistance development | 9 |
pcr ribotype | 9 |
sample collection | 9 |
tetracycline resistant | 9 |
among young | 9 |
specific igg | 9 |
env rhv | 9 |
burgdorferi sensu | 9 |
first report | 9 |
faropenem medoxomil | 9 |
grade i | 9 |
aeruginosa strains | 9 |
took place | 9 |
methicillin resistance | 9 |
igg anti | 9 |
using two | 9 |
meca gene | 9 |
bacterial prostatitis | 9 |
dna microarray | 9 |
one day | 9 |
emerging infectious | 9 |
febrile cough | 9 |
appropriate use | 9 |
spike protein | 9 |
less likely | 9 |
conjugate vaccine | 9 |
positive predictive | 9 |
plasma samples | 9 |
developing countries | 9 |
detection kit | 9 |
resistant acinetobacter | 9 |
surveillance study | 9 |
mic value | 9 |
outpatient antibiotic | 9 |
typing phage | 9 |
three years | 9 |
laboratory standards | 9 |
medical schools | 9 |
aeruginosa isolates | 9 |
pathogens including | 9 |
calculated using | 9 |
false negative | 9 |
disk synergy | 9 |
care centres | 9 |
producing enterobacteriaceae | 9 |
isolates carried | 9 |
determined according | 9 |
control strains | 9 |
environmental samples | 8 |
old male | 8 |
may represent | 8 |
resistant strain | 8 |
antibiotic concentrations | 8 |
influenza vaccine | 8 |
cases patient | 8 |
tissue concentrations | 8 |
diffusion test | 8 |
primary school | 8 |
world regions | 8 |
defined daily | 8 |
mupirocin resistance | 8 |
treatment strategies | 8 |
data show | 8 |
small intestine | 8 |
may result | 8 |
using specific | 8 |
serum levels | 8 |
bp fragment | 8 |
pharmacokinetic parameters | 8 |
commonly detected | 8 |
restriction analysis | 8 |
solid organ | 8 |
one sample | 8 |
systematic reviews | 8 |
group streptococci | 8 |
frequently reported | 8 |
bacillus anthracis | 8 |
aortic valve | 8 |
first study | 8 |
infected cases | 8 |
nile virus | 8 |
infection prevention | 8 |
recent studies | 8 |
seven days | 8 |
gastric biopsies | 8 |
pfge profiles | 8 |
much higher | 8 |
diagnostic criteria | 8 |
primers specific | 8 |
data indicate | 8 |
intestinal microflora | 8 |
fungal infection | 8 |
single nucleotide | 8 |
norfloxacin vitek | 8 |
negative controls | 8 |
observational cohort | 8 |
liver disease | 8 |
necrotizing pancreatitis | 8 |
time series | 8 |
pneumoniae infection | 8 |
enterobacteriaceae strains | 8 |
one year | 8 |
pathogens responsible | 8 |
three groups | 8 |
virus load | 8 |
collected throughout | 8 |
enterococcal isolates | 8 |
will help | 8 |
blood sample | 8 |
found positive | 8 |
validated lc | 8 |
chest ct | 8 |
water cooler | 8 |
direct contact | 8 |
laboratory results | 8 |
toxin genes | 8 |
even though | 8 |
respiratory diseases | 8 |
higher rates | 8 |
vero cells | 8 |
skin infections | 8 |
potent activity | 8 |
viridans group | 8 |
genome sequencing | 8 |
six different | 8 |
individual samples | 8 |
related isolates | 8 |
roc curve | 8 |
peritoneal dialysis | 8 |
legionella pneumophila | 8 |
cardiac surgery | 8 |
acb complex | 8 |
respiratory pathogen | 8 |
positive sample | 8 |
eight patients | 8 |
resistant mutants | 8 |
lamp assay | 8 |
chronic pancreatitis | 8 |
prevalent among | 8 |
horse blood | 8 |
icu stay | 8 |
sputum samples | 8 |
based method | 8 |
therapeutic options | 8 |
safety profile | 8 |
two years | 8 |
molecular analysis | 8 |
high number | 8 |
peptic ulcer | 8 |
current study | 8 |
spa typing | 8 |
medical care | 8 |
molecular diagnostics | 8 |
bact alert | 8 |
included studies | 8 |
new york | 8 |
dairy products | 8 |
commonly isolated | 8 |
younger adults | 8 |
one week | 8 |
bed days | 8 |
vancomycin resistant | 8 |
pcr analysis | 8 |
statin use | 8 |
significant decrease | 8 |
elisa test | 8 |
rna viruses | 8 |
gisa strains | 8 |
synergy test | 8 |
strains carrying | 8 |
new peptide | 8 |
food poisoning | 8 |
two hospitals | 8 |
sample pooling | 8 |
similar results | 8 |
epidemiological data | 8 |
economic impact | 8 |
table shows | 8 |
esbl genes | 8 |
mdr strains | 8 |
eye protection | 8 |
gene sequencing | 8 |
linear regression | 8 |
seven patients | 8 |
significant association | 8 |
laboratory parameters | 8 |
human bocavirus | 8 |
found among | 8 |
gastric biopsy | 8 |
serological assays | 8 |
including multi | 8 |
one virus | 8 |
cause mortality | 8 |
prospective studies | 8 |
viral replication | 8 |
nasopharyngeal aspirates | 8 |
acute lower | 8 |
higher prevalence | 8 |
significant reduction | 8 |
identify patients | 8 |
mic lg | 8 |
general practitioners | 8 |
pfge types | 8 |
higher among | 8 |
crp levels | 8 |
adult population | 8 |
cox regression | 8 |
sentry antimicrobial | 8 |
biochemical tests | 8 |
four strains | 8 |
obtained using | 8 |
mpcr systems | 8 |
nccls criteria | 8 |
clone i | 8 |
antibacterial agents | 8 |
detected among | 8 |
mutation frequency | 8 |
aseptic meningitis | 8 |
generation cephalosporin | 8 |
virus detection | 8 |
kill kinetics | 8 |
requiring intensive | 8 |
critical condition | 8 |
typing method | 8 |
risk score | 8 |
streptococcal infections | 8 |
vaccination coverage | 8 |
infection due | 8 |
infectious agents | 8 |
producing escherichia | 8 |
increased significantly | 8 |
pfge type | 8 |
viral titre | 8 |
log reduction | 8 |
highly sensitive | 8 |
patients presenting | 8 |
nested pcr | 8 |
type fimbriae | 8 |
synovial fluids | 8 |
statistical methods | 8 |
stec strains | 8 |
fold mic | 8 |
sore throat | 8 |
screening test | 8 |
gastrointestinal symptoms | 8 |
also showed | 8 |
antimicrobial consumption | 8 |
pneumoniae atcc | 8 |
haemolytic streptococci | 8 |
different strains | 8 |
control subjects | 8 |
resistant pneumococci | 8 |
resistance determinant | 8 |
response rate | 8 |
viruses detected | 8 |
viridans streptococci | 8 |
sequence types | 8 |
clinical settings | 8 |
viral aetiology | 8 |
critical care | 8 |
method using | 8 |
months mortality | 8 |
three mpcrs | 8 |
west nile | 8 |
requiring hospitalization | 8 |
test result | 8 |
viral meningitis | 8 |
hs hs | 8 |
propensity score | 8 |
false positive | 8 |
independently associated | 8 |
susceptibility profile | 8 |
research production | 8 |
clonal relationship | 8 |
standard deviation | 8 |
antibody responses | 8 |
commonly encountered | 8 |
different hospitals | 8 |
pcr rad | 8 |
mics mg | 8 |
disease burden | 8 |
turnaround times | 8 |
hospitalized adults | 8 |
mupa gene | 8 |
vitro antimicrobial | 8 |
growth rate | 8 |
also included | 8 |
clinical signs | 8 |
available data | 8 |
coronavirus pneumonia | 8 |
moraxella catarrhalis | 8 |
organic acids | 8 |
pvl gene | 8 |
descriptive study | 8 |
cytokine storm | 8 |
lactamase inhibitors | 8 |
laboratory tests | 8 |
validation cohort | 8 |
population analysis | 8 |
significant morbidity | 8 |
salmonella spp | 8 |
melting temperature | 8 |
viral contamination | 8 |
years period | 8 |
ventilated patients | 8 |
may cause | 8 |
viral genome | 7 |
studies reported | 7 |
antibacterial therapy | 7 |
asymptomatic carriers | 7 |
levofloxacin mic | 7 |
matched controls | 7 |
small sample | 7 |
culture results | 7 |
including patients | 7 |
genes among | 7 |
bordetella pertussis | 7 |
phase ii | 7 |
baseline characteristics | 7 |
compartment model | 7 |
receiver operating | 7 |
selected species | 7 |
across different | 7 |
cytotoxin assay | 7 |
two days | 7 |
severe clinical | 7 |
study confirms | 7 |
toxoplasma gondii | 7 |
northern italy | 7 |
one study | 7 |
using supplied | 7 |
viable count | 7 |
ehrlichia anaplasma | 7 |
virulence gene | 7 |
body fluids | 7 |
level gentamicin | 7 |
tertiary hospitals | 7 |
anaerobic infections | 7 |
empirical treatment | 7 |
neutropenic patients | 7 |
neonatal intensive | 7 |
deep sequencing | 7 |
primer pair | 7 |
acid extraction | 7 |
tandem repeat | 7 |
first two | 7 |
hospital setting | 7 |
histological examination | 7 |
results confirm | 7 |
significantly shorter | 7 |
causative pathogen | 7 |
using pfge | 7 |
may increase | 7 |
among strains | 7 |
without respiratory | 7 |
phage typing | 7 |
discriminatory power | 7 |
external quality | 7 |
level mupirocin | 7 |
moxifloxacin concentrations | 7 |
methods used | 7 |
supplied broth | 7 |
clinical use | 7 |
reference strain | 7 |
first hours | 7 |
experimental studies | 7 |
efflux phenotype | 7 |
study entry | 7 |
culture negative | 7 |
target attainment | 7 |
anthrax strains | 7 |
nucleic acids | 7 |
using elisa | 7 |
methicillin susceptible | 7 |
human pathogen | 7 |
triple combinations | 7 |
communityacquired pneumonia | 7 |
febrile illness | 7 |
specimens positive | 7 |
selective media | 7 |
negative control | 7 |
novel des | 7 |
cervical lymphadenitis | 7 |
aureus mrs | 7 |
efflux pumps | 7 |
average age | 7 |
six isolates | 7 |
aortic heart | 7 |
successfully treated | 7 |
mean value | 7 |
clinical relevance | 7 |
mdr phenotype | 7 |
vitek mic | 7 |
per protocol | 7 |
continuous variables | 7 |
kb cells | 7 |
different antibiotics | 7 |
healthcare settings | 7 |
pcr positive | 7 |
possible role | 7 |
salmonella enteritidis | 7 |
rvp assay | 7 |
many countries | 7 |
diagnostic testing | 7 |
patients requiring | 7 |
normally distributed | 7 |
gastrointestinal tract | 7 |
high mic | 7 |
control patients | 7 |
human isolates | 7 |
first positive | 7 |
performance characteristics | 7 |
acquired ampc | 7 |
autoimmune diseases | 7 |
high rates | 7 |
severely ill | 7 |
clonal diversity | 7 |
urine culture | 7 |
organ transplant | 7 |
european union | 7 |
important cause | 7 |
efflux pump | 7 |
risk groups | 7 |
human serum | 7 |
enterobacter cloacae | 7 |
also confirmed | 7 |
western area | 7 |
near future | 7 |
heart valves | 7 |
sample taker | 7 |
used antibiotics | 7 |
membrane protein | 7 |
bacterial aetiology | 7 |
viral inactivation | 7 |
among hospitalized | 7 |
pk analysis | 7 |
po qd | 7 |
healthcare professionals | 7 |
genetic element | 7 |
human infection | 7 |
glycopeptides use | 7 |
new antimicrobial | 7 |
resistant staphylococci | 7 |
human respiratory | 7 |
critical illness | 7 |
invasive pneumococcal | 7 |
tract pathogens | 7 |
antibiotic classes | 7 |
klebsiella species | 7 |
disk test | 7 |
rn muts | 7 |
different time | 7 |
moderate cases | 7 |
mg oral | 7 |
monoclonal antibodies | 7 |
brain tissue | 7 |
first day | 7 |
fq resistance | 7 |
chronic respiratory | 7 |
single mg | 7 |
clinical suspicion | 7 |
index case | 7 |
shock syndrome | 7 |
ermb gene | 7 |
replicate plates | 7 |
east respiratory | 7 |
bacterial pcr | 7 |
wound infections | 7 |
human adenovirus | 7 |
hcv infection | 7 |
thoracic surgery | 7 |
cfia gene | 7 |
labelled probes | 7 |
patient samples | 7 |
total costs | 7 |
treatment cost | 7 |
eortc msg | 7 |
low number | 7 |
organ failure | 7 |
asteroides i | 7 |
bloodstream isolates | 7 |
dosing interval | 7 |
among different | 7 |
two independent | 7 |
atpase gene | 7 |
unknown origin | 7 |
susceptibility pattern | 7 |
copy number | 7 |
acute phase | 7 |
survival rates | 7 |
mtbdr assay | 7 |
major problem | 7 |
time reverse | 7 |
igm antibody | 7 |
ampicillin sulbactam | 7 |
patients suspected | 7 |
production among | 7 |
another study | 7 |
salmonella typhimurium | 7 |
mice treated | 7 |
collection systems | 7 |
positive control | 7 |
phylogenetic group | 7 |
nosocomial transmission | 7 |
positive species | 7 |
transplant patients | 7 |
two main | 7 |
preliminary data | 7 |
cu mm | 7 |
medical devices | 7 |
influenza infections | 7 |
serum concentration | 7 |
cynomolgus monkey | 7 |
susceptibility results | 7 |
ten years | 7 |
pfge analysis | 7 |
orf ab | 7 |
study protocol | 7 |
species isolated | 7 |
toxin gene | 7 |
human disease | 7 |
susceptible isolates | 7 |
phenotypic typing | 7 |
like receptors | 7 |
enrolled patients | 7 |
overall prevalence | 7 |
neisseria meningitidis | 7 |
seven strains | 7 |
hiv infection | 7 |
except one | 7 |
caecal contents | 7 |
will allow | 7 |
appropriate antibiotic | 7 |
diagnostic tool | 7 |
hand washing | 7 |
igg igm | 7 |
pcr system | 7 |
increased likelihood | 7 |
single oral | 7 |
prescription rates | 7 |
incidence rates | 7 |
significant correlation | 7 |
blood concentrations | 7 |
mechanically ventilated | 7 |
attributable mortality | 7 |
clinical situations | 7 |
environmental contamination | 7 |
wide spectrum | 7 |
comparative study | 7 |
become available | 7 |
vitro antibiotic | 7 |
co score | 7 |
postantibiotic effect | 7 |
less frequent | 7 |
samples tested | 7 |
commonly identified | 7 |
isolated species | 7 |
lung cancer | 7 |
control groups | 7 |
grampositive bacteria | 7 |
tonsillar tissue | 7 |
versus vancomycin | 7 |
western europe | 7 |
supplementary data | 7 |
clinical setting | 7 |
resistance profiles | 7 |
primary infection | 7 |
tuberculous abscess | 7 |
saline solutions | 7 |
steady state | 7 |
rd generation | 7 |
particular interest | 7 |
blood donors | 7 |
epidermidis strains | 7 |
antibiotic usage | 7 |
phage therapy | 7 |
toxinotype iii | 7 |
environmental surfaces | 7 |
per day | 7 |
health authorities | 7 |
pneumococcal meningitis | 7 |
reference methods | 7 |
specific clinical | 7 |
visa isolates | 7 |
infection may | 7 |
stem cell | 7 |
mrsa infection | 7 |
automated system | 7 |
human parainfluenza | 7 |
hiv aids | 7 |
molecular mechanisms | 7 |
first line | 7 |
negative staphylococcus | 7 |
seasonal distribution | 7 |
coli atcc | 7 |
poor prognoses | 7 |
form biofilms | 7 |
single step | 7 |
methicillinresistant staphylococcus | 7 |
rank test | 7 |
isolates resistant | 7 |
clonal complexes | 7 |
chronic bronchitis | 7 |
acute pyelonephritis | 7 |
pathogenic strains | 7 |
biofilm production | 7 |
far east | 7 |
may affect | 7 |
mef genes | 7 |
groups according | 7 |
streptococcus viridans | 7 |
preventive measures | 7 |
surgical drainage | 7 |
asymptomatic bacteriuria | 7 |
probable ia | 7 |
mueller hinton | 7 |
viral detection | 7 |
loading dose | 7 |
molecular diagnosis | 7 |
community transmission | 7 |
species distribution | 7 |
isolates contained | 7 |
nitric oxide | 7 |
mssa strains | 7 |
year prospective | 7 |
common cold | 7 |
pooling strategies | 7 |
two university | 7 |
high incidence | 7 |
acquired resistance | 7 |
mononuclear cells | 7 |
hospital wards | 7 |
clinical findings | 7 |
bacteria isolated | 7 |
also identified | 6 |
pneumococcal disease | 6 |
rapid spread | 6 |
microgram ml | 6 |
bus drivers | 6 |
virus disease | 6 |
patients presented | 6 |
tigecycline also | 6 |
ambulatory care | 6 |
respiratory secretions | 6 |
aureus isolated | 6 |
modified intent | 6 |
patients might | 6 |
major abscess | 6 |
patients may | 6 |
children presenting | 6 |
ammassalik district | 6 |
ward closure | 6 |
susceptible strain | 6 |
inflammatory disease | 6 |
diagnostic accuracies | 6 |
antibacterial effect | 6 |
appropriate antimicrobial | 6 |
drug exposure | 6 |
acnes strains | 6 |
mic determination | 6 |
ulcer dyspepsia | 6 |
mssa isolates | 6 |
phenotypic tests | 6 |
national surveillance | 6 |
among isolates | 6 |
viasure test | 6 |
study aims | 6 |
treatment option | 6 |
runny nose | 6 |
sex ratio | 6 |
aureus including | 6 |
urine cultures | 6 |
copies per | 6 |
day old | 6 |
chlamydia psittaci | 6 |
hemorrhagic fever | 6 |
microbiological data | 6 |
infection rate | 6 |
predominant pathogen | 6 |
mobile phones | 6 |
el tor | 6 |
proviral dna | 6 |
cases reported | 6 |
positive anaerobic | 6 |
showed reduced | 6 |
difficile strain | 6 |
bacillus cereus | 6 |
pyogenes isolates | 6 |
assay detected | 6 |
rapid method | 6 |
infected individuals | 6 |
routine laboratory | 6 |
study participants | 6 |
previously reported | 6 |
bpr mg | 6 |
legionella species | 6 |
data showed | 6 |
viable counts | 6 |
european commission | 6 |
results demonstrate | 6 |
renal transplant | 6 |
leukocyte count | 6 |
therapeutic challenge | 6 |
agar diffusion | 6 |
risk patients | 6 |
high levels | 6 |
two weeks | 6 |
innate immune | 6 |
aged broth | 6 |
age distribution | 6 |
natural focuses | 6 |
invasive pulmonary | 6 |
parent strains | 6 |
rare event | 6 |
mic levels | 6 |
large collection | 6 |
otitis externa | 6 |
pylori strains | 6 |
invasive disease | 6 |
control team | 6 |
clinical context | 6 |
nucleotide polymorphisms | 6 |
erythromycin resistant | 6 |
new antimicrobials | 6 |
specimens collected | 6 |
mean serum | 6 |
hospital settings | 6 |
wound healing | 6 |
molecular point | 6 |
molecular detection | 6 |
hts results | 6 |
novel hastv | 6 |
validated hplc | 6 |
using non | 6 |
erythrocyte sedimentation | 6 |
vs days | 6 |
viral sequences | 6 |
barr virus | 6 |
pressure ulcers | 6 |
lung injury | 6 |
family members | 6 |
mic testing | 6 |
rat model | 6 |
cache valley | 6 |
positive organisms | 6 |
study drugs | 6 |
associated coronavirus | 6 |
cq hospitals | 6 |
based hand | 6 |
foot infections | 6 |
rank order | 6 |
clinical improvement | 6 |
fatal disease | 6 |
acid resistance | 6 |
strains exhibited | 6 |
epidemic period | 6 |
quinolone resistant | 6 |
european surveillance | 6 |
nosocomial outbreaks | 6 |
initial empiric | 6 |
antibiotic treatments | 6 |
group compared | 6 |
beta lactam | 6 |
within min | 6 |
birth weight | 6 |
coronary heart | 6 |
pyogenic abscess | 6 |
therapeutic categories | 6 |
crushed tablets | 6 |
urinary antigen | 6 |
vana phenotype | 6 |
fungal pathogens | 6 |
study aimed | 6 |
days later | 6 |
azole resistance | 6 |
highly infectious | 6 |
psoas abscess | 6 |
european society | 6 |
polymicrobial infections | 6 |
participating centres | 6 |
discordant results | 6 |
among healthy | 6 |
cass gall | 6 |
pneumoniae clinical | 6 |
time periods | 6 |
ethics committee | 6 |
pd parameters | 6 |
resistance surveillance | 6 |
positive elisa | 6 |
sample takers | 6 |
teaching hospitals | 6 |
viral aetiologies | 6 |
low risk | 6 |
laboratory data | 6 |
high throughput | 6 |
limited data | 6 |
national institute | 6 |
tissue penetration | 6 |
dengue infection | 6 |
epidemic potential | 6 |
day course | 6 |
microscopic examination | 6 |
chronic gastritis | 6 |
child care | 6 |
control practices | 6 |
cp patients | 6 |
microbiologically evaluable | 6 |
total cost | 6 |
primer pairs | 6 |
brain specimens | 6 |
routine clinical | 6 |
mixed infection | 6 |
phylogenetic analyses | 6 |
type iii | 6 |
antimicrobial stewardship | 6 |
based methods | 6 |
increasing concentrations | 6 |
pressure ulcer | 6 |
adverse reactions | 6 |
bacteria including | 6 |
mefa genes | 6 |
four cases | 6 |
study using | 6 |
samples received | 6 |
bone infections | 6 |
endemic regions | 6 |
urease test | 6 |
treat patients | 6 |
disseminated infection | 6 |
bottled water | 6 |
high degree | 6 |
animal model | 6 |
approximately one | 6 |
specific igm | 6 |
spectrum antimicrobials | 6 |
fully susceptible | 6 |
treatment options | 6 |
early phase | 6 |
primer sets | 6 |
higher sensitivity | 6 |
routinely used | 6 |
asymptomatic infection | 6 |
using real | 6 |
molecular design | 6 |
nccls reference | 6 |
isolates carrying | 6 |
including mrsa | 6 |
lactate dehydrogenase | 6 |
frequently found | 6 |
time mic | 6 |
using different | 6 |
sensu lato | 6 |
future studies | 6 |
mic distribution | 6 |
body weight | 6 |
realtime detection | 6 |
helicobacter spp | 6 |
matrix pooling | 6 |
complicated intra | 6 |
pathogen detection | 6 |
pine core | 6 |
negative samples | 6 |
normal renal | 6 |
identified among | 6 |
simplex virus | 6 |
increasing resistance | 6 |
resistance data | 6 |
treatment period | 6 |
pyrosequencing method | 6 |
pcr negative | 6 |
negative result | 6 |
immunodeficiency diseases | 6 |
care attendance | 6 |
results also | 6 |
laboratory testing | 6 |
times higher | 6 |
particular importance | 6 |
specimen collection | 6 |
bacterial dna | 6 |
serial dilutions | 6 |
demographic characteristics | 6 |
antigen test | 6 |
liver transplantation | 6 |
shelter hospital | 6 |
nucleotide sequence | 6 |
acne patients | 6 |
enterovirus rhinovirus | 6 |
using spss | 6 |
microbiological analysis | 6 |
hospitalized children | 6 |
medical resources | 6 |
pneumonia requiring | 6 |
may contribute | 6 |
also evaluated | 6 |
laboratory diagnosis | 6 |
peritonitis model | 6 |
new agents | 6 |
normal limits | 6 |
dna fragments | 6 |
rd period | 6 |
lesser extent | 6 |
lyme disease | 6 |
least days | 6 |
less frequently | 6 |
mupirocin resistant | 6 |
linked immunosorbent | 6 |
efflux systems | 6 |
operating characteristic | 6 |
multicentre study | 6 |
restriction enzyme | 6 |
reactive arthritis | 6 |
rrna sequencing | 6 |
innate immunity | 6 |
pneumoniae infections | 6 |
isolates harboured | 6 |
main transmission | 6 |
qc strains | 6 |
diseases society | 6 |
using dna | 6 |
pk parameters | 6 |
potential risk | 6 |
adjunctive therapy | 6 |
pool size | 6 |
liver function | 6 |
sequence data | 6 |
significant role | 6 |
main cause | 6 |
drug efflux | 6 |
standard methodology | 6 |
borrelia burgdorferi | 6 |
nucleotide sequences | 6 |
standards institute | 6 |
study compared | 6 |
study demonstrated | 6 |
causative agents | 6 |
realtime pcr | 6 |
animal bites | 6 |
diagnostic tools | 6 |
written consent | 6 |
single intravenous | 6 |
data support | 6 |
rhinovirus infections | 6 |
baba gene | 6 |
antiviral drugs | 6 |
predominant pathogens | 6 |
acid sequences | 6 |
clonal spread | 6 |
direct detection | 6 |
horizontal transmission | 6 |
cps pcr | 6 |
quality controls | 6 |
coli isolated | 6 |
widely distributed | 6 |
strains studied | 6 |
important gram | 6 |
corneal scrapes | 6 |
core wood | 6 |
pathogens isolated | 6 |
resistant bacterial | 6 |
recent reports | 6 |
dna copies | 6 |
imipenem mic | 6 |
antigen tests | 6 |
monoclonal antibody | 6 |
drug concentration | 6 |
conjunctival swabs | 6 |
aspergillus fumigatus | 6 |
aureus bacteraemia | 6 |
bl mice | 6 |
vdrl virablot | 6 |
lactamase inhibitor | 6 |
immunosorbent assay | 6 |
experimental conditions | 6 |
assessed using | 6 |
suspected cases | 6 |
different methods | 6 |
specific rt | 6 |
class integron | 6 |
flow conditions | 6 |
among hcws | 6 |
vor iv | 6 |
dosing regimens | 6 |
tigecycline presented | 6 |
intact tablets | 6 |
high concentrations | 6 |
pk data | 6 |
different pfge | 6 |
increasing prevalence | 6 |
host immune | 6 |
may indicate | 6 |
agar supplemented | 6 |
low quality | 6 |
also significantly | 6 |
regression analyses | 6 |
clinical impact | 6 |
erm genes | 6 |
rapid influenza | 6 |
sars outbreak | 6 |
adjusted mueller | 6 |
pdf inhibitor | 6 |
preterm delivery | 6 |
acute heart | 6 |
fold lower | 6 |
penicillin susceptibility | 6 |
influenza diagnostic | 6 |
multiple mechanisms | 6 |
classification algorithm | 6 |
phenotypic resistance | 6 |
different patients | 6 |
cell transplant | 6 |
molecular tests | 6 |
hospital discharge | 6 |
mild disease | 6 |
different genetic | 6 |
significantly less | 6 |
swab specimens | 6 |
quaternary ammonium | 6 |
stationary phase | 6 |
topical ocular | 6 |
population pk | 6 |
efflux positive | 6 |
reverse transcriptase | 6 |
bacterial contamination | 6 |
wuchang district | 6 |
nine isolates | 6 |
without fever | 6 |
rate constant | 6 |
beta lactamase | 6 |
positive viral | 6 |
severe renal | 6 |
patients required | 6 |
tested negative | 6 |
acinetobacter baumanii | 6 |
normal range | 6 |
antibody response | 6 |
probably due | 6 |
mg loading | 6 |
ampc beta | 6 |
study conducted | 6 |
mutation frequencies | 6 |
replicating virus | 6 |
transcription loop | 6 |
type beta | 6 |
francisella tularensis | 6 |
tuberculous sd | 6 |
patients within | 6 |
tested compounds | 6 |
mg twice | 6 |
intermediate resistance | 6 |
data presented | 6 |
salmonella enterica | 6 |
children less | 6 |
biochemical identification | 6 |
conjugation experiments | 6 |
vanb genes | 6 |
transmission setting | 6 |
causative pathogens | 6 |
nccls recommendations | 6 |
atypical bacteria | 6 |
one hour | 6 |
disease caused | 6 |
sudden onset | 6 |
lc pcr | 6 |
older patients | 6 |
direct microscopy | 6 |
acute infection | 6 |
active agents | 6 |
pharmacokinetic data | 6 |
compared groups | 6 |
primary immunodeficiency | 6 |
glucose non | 6 |
appropriate treatment | 6 |
relative risk | 6 |
rna copies | 6 |
may occur | 6 |
normal intestinal | 6 |
health service | 6 |
genetic elements | 5 |
culture bottles | 5 |
practice guidelines | 5 |
second half | 5 |
forming units | 5 |
peak mic | 5 |
multivariate logistic | 5 |
treated group | 5 |
concentration range | 5 |
postoperative pneumonia | 5 |
mutant prevention | 5 |
erg gene | 5 |
lnz treatment | 5 |
isoelectric focusing | 5 |
species specific | 5 |
except hiv | 5 |
enterococcus species | 5 |
gene cassette | 5 |
emergency departments | 5 |
among women | 5 |
severity index | 5 |
medical center | 5 |
many years | 5 |
mrsa clone | 5 |
strains expressing | 5 |
chi square | 5 |
mini kit | 5 |
general practice | 5 |
one respiratory | 5 |
prevention concentration | 5 |
study indicates | 5 |
anaerobic conditions | 5 |
antifungal drugs | 5 |
inappropriate use | 5 |
heart infusion | 5 |
showed lower | 5 |
point mutations | 5 |
promoter region | 5 |
time nasba | 5 |
two consecutive | 5 |
antimicrobial drugs | 5 |
quality assessment | 5 |
acrb mutant | 5 |
previously associated | 5 |
testing methods | 5 |
shigella spp | 5 |
college station | 5 |
new molecular | 5 |
every day | 5 |
serum sample | 5 |
acute cough | 5 |
ctx lg | 5 |
brucella isolates | 5 |
five strains | 5 |
ampc enzymes | 5 |
staphylococcus haemolyticus | 5 |
study date | 5 |
health protection | 5 |
caga gene | 5 |
clinical presentations | 5 |
integrated analysis | 5 |
fungicidal activity | 5 |
strongly associated | 5 |
gram staining | 5 |
fresh broth | 5 |
naturally occurring | 5 |
young age | 5 |
opportunistic pathogens | 5 |
rna detection | 5 |
time dependent | 5 |
growing concern | 5 |
eu clone | 5 |
four regions | 5 |
following criteria | 5 |
chronic medical | 5 |
impact factor | 5 |
gut microbiota | 5 |
mrsa strain | 5 |
type enzymes | 5 |
nocardia isolates | 5 |
six consecutive | 5 |
main objective | 5 |
last two | 5 |
ear fluid | 5 |
conventional culture | 5 |
blood sera | 5 |
detected viruses | 5 |
costs per | 5 |
pfge profile | 5 |
plastic surface | 5 |
elbow pji | 5 |
quantitative pcr | 5 |
chronic conditions | 5 |
bacterial strain | 5 |
halo subgroup | 5 |
chlamydia pnenmoniae | 5 |
class glycylcycline | 5 |
infect dis | 5 |
dna sequences | 5 |
microarray technology | 5 |
nine strains | 5 |
common source | 5 |
consecutive seasons | 5 |
low mic | 5 |
cvc blood | 5 |
active surveillance | 5 |
teta gene | 5 |
phase growth | 5 |
south korea | 5 |
chinese medicine | 5 |
encoding phage | 5 |
biopsy specimens | 5 |
ceftriaxone plus | 5 |
will increase | 5 |
genetic markers | 5 |
probe prodesse | 5 |
eligible patients | 5 |
asymptomatic hcws | 5 |
asymptomatic individuals | 5 |
also analysed | 5 |
cdt genes | 5 |
secondary infection | 5 |
clinical importance | 5 |
verigene rv | 5 |
well established | 5 |
susceptible staphylococcus | 5 |
recent outbreaks | 5 |
toxigenic clostridium | 5 |
moxifloxacin group | 5 |
complete clinical | 5 |
burn centre | 5 |
microbiologic efficacy | 5 |
elevated ast | 5 |
among clinical | 5 |
detected respiratory | 5 |
dose adjustments | 5 |
aureus colonization | 5 |
faecium clones | 5 |
vaginal swabs | 5 |
spontaneous sd | 5 |
agar medium | 5 |
coronavirus infection | 5 |
individual tests | 5 |
secondary bacterial | 5 |
oxacillin resistance | 5 |
newly developed | 5 |
wound colonisation | 5 |
clonal types | 5 |
official publication | 5 |
clinical criteria | 5 |
placenta amnion | 5 |
commonly occurring | 5 |
laboratory medicine | 5 |
colonised patients | 5 |
dressing changes | 5 |
patient characteristics | 5 |
expert opinion | 5 |
body mass | 5 |
prevalence survey | 5 |
culture positivity | 5 |
salmonella serotypes | 5 |
creatinine clearance | 5 |
amplified products | 5 |
clinical guidelines | 5 |
infected children | 5 |
glomerular filtration | 5 |
serious adverse | 5 |
valent pneumococcal | 5 |
isolates revealed | 5 |
new insights | 5 |
culture plates | 5 |
although similar | 5 |
time period | 5 |
frequently associated | 5 |
strain identification | 5 |
may improve | 5 |
study demonstrates | 5 |
infection worldwide | 5 |
aureus carriage | 5 |
blood levels | 5 |
inoculated onto | 5 |
without previous | 5 |
use density | 5 |
outcomes included | 5 |
oral gavage | 5 |
retrospectively reviewed | 5 |
community setting | 5 |
mics values | 5 |
new approach | 5 |
ampc producers | 5 |
enrichment broth | 5 |
antibiotics used | 5 |
treponema vdrl | 5 |
bacteroides species | 5 |
bacterial suspensions | 5 |
surveillance data | 5 |
national guidelines | 5 |
bacteroides strains | 5 |
phenotypic methods | 5 |
pd models | 5 |
routine testing | 5 |
intracellular activity | 5 |
strong association | 5 |
standard protocols | 5 |
moxifloxacin showed | 5 |
viral transport | 5 |
well plates | 5 |
microtitre plate | 5 |
phage types | 5 |
lumbar puncture | 5 |
different clinical | 5 |
throat swab | 5 |
test methods | 5 |
public hospitals | 5 |
venous catheter | 5 |
kidney disease | 5 |
prospectively included | 5 |
vanb phenotype | 5 |
rhinovirus transmission | 5 |
nursing home | 5 |
faecal specimens | 5 |
foreign travel | 5 |
two multiplex | 5 |
sputum production | 5 |
commonly associated | 5 |
mic results | 5 |
total use | 5 |
valve ie | 5 |
lyme borreliosis | 5 |
among adults | 5 |
genetic determinants | 5 |
laminar flow | 5 |
campylobacter species | 5 |
pharmacodynamic model | 5 |
anaerobic cocci | 5 |
hajj pilgrimage | 5 |
fomite transmission | 5 |
mouse models | 5 |
concentration effect | 5 |
vivo activity | 5 |
epidemic spread | 5 |
healthcare system | 5 |
test performance | 5 |
data set | 5 |
effective treatment | 5 |
vp gene | 5 |
samples using | 5 |
new emerging | 5 |
antifungal treatment | 5 |
increasingly important | 5 |
cardiovascular diseases | 5 |
gastric mucosa | 5 |
microbiological methods | 5 |
developed countries | 5 |
patient age | 5 |
skin nasal | 5 |
plasmid mediated | 5 |
four hundred | 5 |
among hospital | 5 |
typhimurium dt | 5 |
characteristic curve | 5 |
higher viral | 5 |
normal phenotype | 5 |
combined treatment | 5 |
broth dilution | 5 |
slightly higher | 5 |
collected data | 5 |
positive tests | 5 |
gyra gene | 5 |
genotype mtbdr | 5 |
tandem repeats | 5 |
mrkd genes | 5 |
previous month | 5 |
also associated | 5 |
i specimens | 5 |
high specificity | 5 |
mutations associated | 5 |
diagnostic oral | 5 |
virus type | 5 |
broth supplemented | 5 |
whole genome | 5 |
also performed | 5 |
three times | 5 |
fluid concentrations | 5 |
treated subjects | 5 |
lassa fever | 5 |
inflammatory responses | 5 |
three main | 5 |
literature search | 5 |
agents still | 5 |
learning algorithms | 5 |
isolates produced | 5 |
lg equiv | 5 |